A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)


To compare the bronchodilator efficacy of ipratropium plus salbutamol (Combivent) with salbutamol alone given every 20 minutes for three doses in asthmatic children with severe acute exacerbation

Full Title of Study: “A Comparison of Combivent┬« UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) in a Double-Blind Efficacy and Safety Study in Asthmatic Children With Severe Acute Exacerbation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: November 2003

Detailed Description

A Comparison of Ipratropium 500mcg and salbutamol 2.5mg (Combivent UDV) and salbutamol UDV alone (2.5mg) in a Double-blind, Efficacy and Safety Study in Asthmatic Children with Severe Acute Exacerbation

Study Hypothesis:

Several studies, including a study conducted in an emergency room setting, demonstrated that the addition of ipratropium bromide, an anticholinergic drug, to standard salbutamol therapy significantly improves pulmonary function as compared to salbutamol alone.


Ipratropium bromide 500 mcg plus salbutamol 2.5mg (Combivent) vs salbutamol (2.5mg) alone given every 20 minutes for 3 doses


  • Drug: ipratropium plus salbutamol UDV
  • Drug: salbutamol UDV

Clinical Trial Outcome Measures

Primary Measures

  • The proportion of patients showing improvement in asthma severity scores from severe at baseline to mild at the end of the treatment

Secondary Measures

  • Change in asthma severity scores from baseline to end of treatment; number of patients needing hospitalization; number of rescue medications; oxygen saturation, number of discharged patients revisiting the ER/doctors clinic

Participating in This Clinical Trial

Inclusion Criteria

1. All patients must have a known history of asthma and present to the hospital/clinic with severe acute exacerbation.

2. Male or female patients 2 to 10 years of age.

3. Parents or legal guardians of patients must sign an Informed Consent Form prior to participation in the trial.

Exclusion Criteria

1. Patients with known or suspected hypersensitivity to study drugs

2. Patients with medical condition that would contraindicate the use of beta2-adrenergic or anticholinergic medications

3. Patients with first wheezing episode only

4. Prior intubation for asthma for more than 24 hours

5. Patients who used ipratropium within six hours prior to consultation

6. Patients with concurrent stridor or possible presence of intra-thoracic foreign body

7. Patients with disease known to have chronic effect on respiratory function ( e.g., cystic fibrosis or cardiac disease)

8. Patients requiring immediate resuscitation or airway intervention

9. With psychiatric disease or psychosocial problems

10. Patients on other investigational drugs or have used any other investigational drugs within the past month

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: 10 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boehringer Ingelheim
  • Overall Official(s)
    • Boehringer Ingelheim Study Coordinator, Study Chair, B.I. (Phil) Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.